Valion Bio, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Valion Bio, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 3.3 times its market value (net cash). Higher than 98% of Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 44,407% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 97% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / +438%In 3 years sales changed by -100% while total assets changed by +438%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
3.3× cashCash, after subtracting all debt, is 3.3 times its market value (net cash).
Higher than 98% of Healthcare companies in United States.
Tangible Assets Ratio
93%Of every $100 the company owns, $93 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 66% of Healthcare companies in United States.
Tangible Net Worth Ratio
87%Of every $100 of net worth, $87 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 68% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Valion Bio, Inc. made a loss over the last year. Valion Bio, Inc. owes $0.87 for every $1 it owns. Valion Bio, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossValion Bio, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.44The share price is 0.44 times Valion Bio, Inc.'s book value per share, lower than 93% of Healthcare companies in United States.
Market cap
$2 MThe total market value of all of Valion Bio, Inc.'s shares at today's price (share price × number of shares), smaller than 98% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$4 MWhat Valion Bio, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.18Net worth divided by the number of shares. The share price of $0.96 is 0.4 times this, which is the P/B above.
Return on equity (ROE)
-459.5%Valion Bio, Inc. lost 459.5% of its shareholders' money over the last year, lower than 93% of Healthcare companies in United States.
Owes vs Owns
0.87×Valion Bio, Inc. owes $0.87 for every $1 it owns (high), higher than 81% of Healthcare companies in United States.
Dividend yield
NoneValion Bio, Inc. does not currently pay a dividend.
Profit growth
LossValion Bio, Inc. made a loss in each of the last two years.
Interest cover
Not coveredValion Bio, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashValion Bio, Inc. held $6 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Valion Bio, Inc.: $2 M ÷ $4 M (30 Jun 2026) = 0.4.
What is Valion Bio, Inc.'s return on equity?
Valion Bio, Inc. lost 459.5% of its shareholders' money over the last year, lower than 93% of Healthcare companies in United States.
How much does Valion Bio, Inc. owe compared with what it owns?
Valion Bio, Inc. owes $0.87 for every $1 it owns (high), higher than 81% of Healthcare companies in United States.
Does Valion Bio, Inc. pay a dividend?
No. Valion Bio, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.